Last updated: February 20, 2026
Brimonidine tartrate, a selective alpha-2 adrenergic receptor agonist, is primarily used to lower intraocular pressure in patients with glaucoma or ocular hypertension. The drug is available in various formulations, including eye drops and oral tablets. Key suppliers globally include both generic manufacturers and brand-name producers.
Leading Manufacturers and Suppliers
| Company |
Location |
Production Capacity |
Notable Products |
Regulatory Approvals |
| Santen Pharmaceutical |
Japan |
High-volume manufacturing |
Alphagan, Mirvaso |
Japanese FDI, FDA, EMA |
| Allergan (AbbVie) |
Ireland |
Large-scale production |
Alphagan P |
FDA, EMA |
| Zhaoke (Zhaoke Pharmaceutical) |
China |
Growing capacity |
Brimonidine eye drops |
CFDA/China NMPA |
| Sun Pharmaceutical Industries |
India |
Extensive manufacturing |
Generic brimonidine formulations |
CDSCO, FDA approval for generics |
| Teva Pharmaceutical Industries |
Israel |
Global supply |
Generic formulations |
FDA, EMA |
| Chengdu Hile Bio-Pharmaceutical |
China |
Focused on ophthalmic APIs |
Brimonidine tartrate API |
China NMPA |
| Zhuhai Rundu Pharmaceutical |
China |
API manufacturing |
Brimonidine tartrate API |
China NMPA |
API Suppliers for Brimonidine Tartrate
Suppliers producing the active pharmaceutical ingredient (API) include:
- Chengdu Hile Bio-Pharmaceutical (China): API production since 2018, supplies to generic manufacturers.
- Zhejiang NHU Co., Ltd. (China): API manufacturing, with exports to global markets.
- Zhaoke Pharmaceutical (China): API production, expanding capacity.
- Gansu Zhifeng Pharmaceutical (China): Supplies APIs to generic producers.
- Teva API Division (Israel): API production with global distribution agreements.
Regulatory and Market Dynamics
Brimonidine tartrate API is primarily produced in China and India, with manufacturing facilities holding Good Manufacturing Practice (GMP) certifications from respective authorities. Countries such as the US, EU, and Japan rely on imported APIs from these regions.
The market is characterized by high competition among generic manufacturers. Brand-name drugs like Alphagan retail for approximately $150 per 10 mL bottle in the US, while generics are priced around $40–$70.
Supply Chain and Market Trends
- API Manufacturing Shift: An increase in API production capacity in China and India to meet global demand, reducing overall costs.
- Regulatory Approvals: Exporting companies often seek approvals from bodies like the FDA, EMA, or NMPA to access international markets.
- Patent Status: Brimonidine tartrate's patents have expired in the US and EU, fostering generic proliferation.
- Quality Standards: Suppliers must adhere to GMP standards, especially for APIs sourced for US and European markets.
Summary of Major Suppliers
- Brands: Santen, Allergan (now part of AbbVie).
- Generics: Sun Pharma, Teva, Chengdu Hile.
- API Producers: Chinese companies dominate API manufacturing, with a growing presence from Indian firms.
Key Considerations for Buyers
- Quality Certifications: Ensure suppliers meet GMP standards.
- Regulatory Approvals: Confirm API and finished drug approval for target markets.
- Capacity & Lead Times: Evaluate production scalability and delivery schedules.
- Pricing: Balance cost savings against quality and compliance.
Closing Notes
Brimonidine tartrate supply is heavily reliant on Chinese and Indian API manufacturers, with leading brand products produced mostly in Japan and Ireland. The market's competitive landscape favors generic manufacturers due to patent expirations, enabling cost-effective options in developed markets.
Key Takeaways
- China and India are the primary API suppliers for brimonidine tartrate.
- Major brand manufacturers include Santen and Allergan (AbbVie).
- Generic competition is high, leading to lower prices.
- API suppliers must adhere to GMP and regulatory standards for international markets.
- Supply chain stability depends on regulatory approvals and manufacturing capacity in sourcing countries.
FAQs
Q1: Who are the main API suppliers for brimonidine tartrate?
A1: Chengdu Hile Bio-Pharmaceutical, Zhejiang NHU, and Gansu Zhifeng are leading Chinese API producers. Teva and other global firms also produce API for international markets.
Q2: Are there patent restrictions on brimonidine tartrate?
A2: Patents have expired in the US and EU, allowing generic manufacturers to produce and sell brimonidine tartrate formulations.
Q3: Which countries are key markets for licensed brimonidine products?
A3: United States, European Union, Japan, and China.
Q4: What quality standards are required for API suppliers?
A4: GMP compliance, ≥ European GMP certifications, or FDA approval for APIs intended for these markets.
Q5: How does the price of generics compare to branded products?
A5: Generics typically cost 60-75% less than branded equivalents, with prices ranging from $40 to $70 for a 10 mL bottle.
References
- U.S. Food and Drug Administration. (2022). Drug Market Reports.
- European Medicines Agency. (2022). Ophthalmic drugs overview.
- Chinese National Medical Products Administration. (2022). API manufacturing standards.
- Market data reports. (2022). Global ophthalmic pharmaceuticals.
- Pharma intelligence databases. (2022). API manufacturing and supply chain.
